Components of a Report
With convenient online access, MI Profile™ reports from Caris Life Sciences® provide the clinically relevant information oncologists need to individualize cancer treatment.
Caris Molecular Intelligence® Summary
Each MI Profile report provides a summary listing of agents associated with potential clinical benefit, agents associated with potential lack of clinical benefit, and relevant, open clinical trials, as well as patient-specific information such as biomarker expression levels and pathologic diagnosis.
A breakdown of biomarker results used to provide a list of agents associated with potential clinical benefit and a list of agents associated with potential lack of clinical benefit. This information includes:
- Agents associated with specific biomarkers
- Method/technology used for biomarker analysis
- Biomarker result
- Clinical association (with benefit or with lack of benefit)
- Level of evidence associated with agent/ biomarker combinations
Clinical Trials Connector™
The Clinical Trials Connector identifies open, relevant clinical trials based on the patient’s tumor type and biomarkers expressed. Each Caris report provides additional information related to the trials, including: protocol number, study title, phase, featured drug and biomarker, and locations accepting subjects.
Literature Level of Evidence and Biomarker Descriptions
An analysis of scientific literature to provide a level of evidence supporting recommended agents associated with potential clinical benefit and agents associated with potential lack of clinical benefit.
Detailed Report of all Analyses Performed
A breakdown of specific results for all biomarkers as analyzed by IHC, FISH and CISH, PCR, DNA sequence analysis and Next-Generation Sequencing.
A description of each of the relevant biomarkers, as well as a summary of these biomarkers’ roles in cancer biology and treatment.